- Home
- NPFD vs PGEN Comparison
NPFD vs PGEN Comparison
Compare NPFD & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPFD
- PGEN
- Stock Information
- Founded
- NPFD 2021
- PGEN 1998
- Country
- NPFD United States
- PGEN United States
- Employees
- NPFD N/A
- PGEN N/A
- Industry
- NPFD Trusts Except Educational Religious and Charitable
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NPFD Finance
- PGEN Health Care
- Exchange
- NPFD Nasdaq
- PGEN Nasdaq
- Market Cap
- NPFD 462.7M
- PGEN 475.2M
- IPO Year
- NPFD N/A
- PGEN N/A
- Fundamental
- Price
- NPFD $19.39
- PGEN $1.85
- Analyst Decision
- NPFD
- PGEN Strong Buy
- Analyst Count
- NPFD 0
- PGEN 3
- Target Price
- NPFD N/A
- PGEN $6.00
- AVG Volume (30 Days)
- NPFD 64.7K
- PGEN 2.2M
- Earning Date
- NPFD 01-01-0001
- PGEN 08-13-2025
- Dividend Yield
- NPFD 6.28%
- PGEN N/A
- EPS Growth
- NPFD N/A
- PGEN N/A
- EPS
- NPFD N/A
- PGEN N/A
- Revenue
- NPFD N/A
- PGEN $4,201,000.00
- Revenue This Year
- NPFD N/A
- PGEN $256.94
- Revenue Next Year
- NPFD N/A
- PGEN $759.81
- P/E Ratio
- NPFD N/A
- PGEN N/A
- Revenue Growth
- NPFD N/A
- PGEN N/A
- 52 Week Low
- NPFD $14.50
- PGEN $0.65
- 52 Week High
- NPFD $18.07
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- NPFD 60.36
- PGEN 68.77
- Support Level
- NPFD $19.28
- PGEN $1.56
- Resistance Level
- NPFD $19.50
- PGEN $2.04
- Average True Range (ATR)
- NPFD 0.19
- PGEN 0.11
- MACD
- NPFD 0.02
- PGEN 0.04
- Stochastic Oscillator
- NPFD 68.97
- PGEN 70.00
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.